A CASE OF MALE BREAST CANCER THAT DEVELOPED DURING ENDOCRINE THERAPY FOR PROSTATE CANCER

PURPOSE To develop recommendations concerning the management of male breast cancer. METHODS ASCO convened an Expert Panel to develop recommendations based on a systematic review and a formal consensus process. RESULTS Twenty-six descriptive reports or observational studies met eligibility criteria and formed the evidentiary basis for the recommendations. RECOMMENDATIONS Many of the management approaches used for men with breast cancer are like those used for women. Men with hormone receptor–positive breast cancer who are candidates for adjuvant endocrine therapy should be offered tamoxifen for an initial duration of five years; those with a contraindication to tamoxifen may be offered a gonadotropin-releasing hormone agonist/antagonist plus aromatase inhibitor. Men who have completed five years of tamoxifen, have tolerated therapy, and still have a high risk of recurrence may be offered an additional five years of therapy. Men with early-stage disease should not be treated with bone-modifying agents to prevent recurrence, but could still receive these agents to prevent or treat osteoporosis. Men with advanced or metastatic disease should be offered endocrine therapy as first-line therapy, except in cases of visceral crisis or rapidly progressive disease. Targeted systemic therapy may be used to treat advanced or metastatic cancer using the same indications and combinations offered to women. Ipsilateral annual mammogram should be offered to men with a history of breast cancer treated with lumpectomy regardless of genetic predisposition; contralateral annual mammogram may be offered to men with a history of breast cancer and a genetic predisposing mutation. Breast magnetic resonance imaging is not recommended routinely. Genetic counseling and germline genetic testing of cancer predisposition genes should be offered to all men with breast cancer.

Download Full-text

A Synchronous Diagnosis of Metastatic Male Breast Cancer and Prostate Cancer

Journal of Investigative Medicine High Impact Case Reports ◽

10.1177/2324709619847230 ◽

2019 ◽

Vol 7 ◽

pp. 232470961984723

Author(s):

Leila Moosavi ◽

Phyllis Kim ◽

An Uche ◽

Everardo Cobos

Keyword(s):

Breast Cancer ◽

Prostate Cancer ◽

Male Breast Cancer ◽

Breast Cancer Diagnosis ◽

Male Breast ◽

Breast Mass ◽

Medical Attention ◽

Cancer History ◽

History Of ◽

The Right

In this article, we present a patient diagnosed synchronously with metastatic male breast cancer and prostate cancer. This is a 63-year-old male and recent immigrant from Nigeria, who sought medical attention for progressively worsening of shortness of breath and acute progression of a chronic right breast mass. An invasive breast carcinoma was diagnosed by the core biopsy of the right breast mass. Within 2 months of his breast cancer diagnosis, the patient also was diagnosed with prostate adenocarcinoma after being worked up for urinary retention. By presenting this patient with a synchronous diagnosis with metastatic male breast cancer and prostate cancer, history of chronic right breast mass, and gynecomastia, we speculate on possible cancer etiologies and risk factors.

Download Full-text

Relation between male breast cancer and prostate cancer

British Journal of Cancer ◽

10.1038/bjc.1980.313 ◽

1980 ◽

Vol 42 (5) ◽

pp. 787-790 ◽

Cited By ~ 15

Author(s):

L H Sobin ◽

M Sherif

Keyword(s):

Breast Cancer ◽

Prostate Cancer ◽

Male Breast Cancer ◽

Male Breast

Download Full-text

Male breast cancer: Our experience

Journal of Clinical Oncology ◽

10.1200/jco.2006.24.18_suppl.10733 ◽

2006 ◽

Vol 24 (18_suppl) ◽

pp. 10733-10733

Author(s):

L. Tozzi ◽

C. D’Addetta ◽

M. Bisceglia ◽

R. Murgo ◽

G. Cilenti ◽

...

Keyword(s):

Breast Cancer ◽

Prostate Cancer ◽

Risk Factors ◽

Male Breast Cancer ◽

Dietary Factors ◽

Male Breast ◽

Axillary Lymph ◽

Cancer History ◽

Family Cancer History ◽

Disease Free

10733 Background: Male breast is an uncommon disease, accounting for <1% of all malingnancies in the man. In contrast to women with breast cancer, men with breast cancer are older and have more advanced disease. Methods: Data regarding 25 male patients who underwent surgery for breast cancer in the our Istitution between January 1994 and December 2005 were analyzed. The main characteristics of these patients included: median age 64 years (range 32–87); positivity family cancer history: specific 4 pts, non-specific 3, no circumstance 18; risk factors: obesity 6 pts, gynaecomastia 4, diabetes 5, liver transplant 1. Five cases of second neoplasia were observed: 2 patient with prostate cancer, 1 synchronous colon carcinoma, 1 head and neck cancer, 1 pancreatic cancer. Results: All but one pts (with syncrhronous metastases at presentation) underwent mastectomy. Pathological characteristics included: pT1 tumors 3 pts (12%); pT2 7 pts (28%), pT3 2 (8%), pT4 13 (52 %); infiltrating ductal carcinomas in 88% of cases; axillary lymph node involvement in 12 (50%); 22 patients had estrogen- and progesterone-receptor positive tumors, 2 pts negative, 1 pts unknown. After surgery 14 pts received RT, 13 pts hormonotherapy and 16 patients adjuvant chemotherapy (7 CMF, 9 anthracyclin-based therapy). Median disease free survival was 41.5 months (range 5–116).With a median follow-up of 66 months, we observed 12 deaths (10 pts for progressive disease) and the overall survival rate was 52% (13 pts; 11 disease-free). According to the family cancer history we observed 5/7 (71%) and 7/18 (39%) deaths in positive and negative cases, respectively. Conclusions: The approach to male breast cancer patients is similar to that for female patients. Our data confirm the suspected epidemiologic risk factors such as prostate cancer, gynecomastia and dietary factors; furthermore, cases with family cancer history seems to have a worse prognosis. No significant financial relationships to disclose.

Download Full-text

Association of male breast cancer and prostate cancer: A large population based study.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.1541 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 1541-1541

Author(s):

Shaheenah S. Dawood ◽

Joanne Ngeow Yuen Yie ◽

Paul N. Mainwaring ◽

Sudeep Gupta ◽

Javier Cortes ◽

...

Keyword(s):

Breast Cancer ◽

Prostate Cancer ◽

Male Breast Cancer ◽

Large Population ◽

Population Based ◽

Male Breast ◽

Population Based Study

Download Full-text

Male breast cancer: Epidemiological evaluation and clinical outcomes.

Journal of Clinical Oncology ◽

10.1200/jco.2020.38.15_suppl.e13619 ◽

2020 ◽

Vol 38 (15_suppl) ◽

pp. e13619-e13619

Author(s):

Edla Renata Cavalcante ◽

Katia Regina Marchetti ◽

Jamile Almeida Silva ◽

Laura Testa

Keyword(s):

Breast Cancer ◽

Endocrine Therapy ◽

Male Breast Cancer ◽

Cox Regression ◽

Sao Paulo ◽

Male Breast ◽

Rank Test ◽

São Paulo ◽

Male Population ◽

Female Population

e13619 Background: Male breast cancer (BC) is a rare neoplasia, with a risk of 1:1.000 in USA. Data from Sao Paulo Cancer Registry has shown that BC adjusted incidence rates is about 1.21 per 100,000 at the period from 2001 to 2005, but there is no incidence data for the whole country. Methods: We conducted a unicentric retrospective cohort, with histologically proven male BC patients whose first appointment was between 2008 and 2018 at Instituto do Câncer do Estado de São Paulo in Brazil. The primary endpoint was OS according to metastatic status and initial staging. OS and RFS were analyzed by Kaplan–Meier method and the difference calculated by log-rank test; reported hazard ratios by univariate Cox Models and P-values by score test. Multivariate analysis was calculated through COX regression. Results: 89 male BC patients were accessed, average age at diagnosis was 63.3 yeas-old. 84.2% had carcinoma of no special type (88,7% estrogen positive receptor, 84,2% progesterone positive receptor). When Charlson Comorbidity Index (CCI) was calculated, most (23.5%) were ≥ 7 (10-year survival: 0%), being 17.9% stage IV. Mastectomy was performed at 73% patients, 38.2% received adjuvant chemotherapy; 44.9% received adjuvant radiotherapy and 64% received adjuvant endocrine therapy (94.7% tamoxifen). For metastatic disease, endocrine therapy was the first option in 52%. Median OS was 75 months (95% CI, 39.2-110.7) in M0 and 39 months (95% CI, 25,2–52,8) in M1 ( p = 0.001). CCI showed be an independent death factor (HR 0.37, 95% CI, 0.17-0.8, p = 0.011). Median RFS was 97 months [95% CI, 47.3–146.7]. When BMI was evaluated for patients with obesity (> 30) there was no difference in disease relapse ( p = 0.29). Conclusions: Our results are consistent with those from previous literature, regarding histology, biomarkers and later stage at diagnosis. A quarter of our patients had high CCI and this could had impacted on best treatment option choices. Treatment approaches use to be similar from those of female population. However, as disease biology and hormonal physiology are different between gender, there is a lack of specific protocols and trials in male population.

Download Full-text

Potential Benefits of Pre-emptive PGx Testing in Male Breast Cancer Patients

INNOVATIONS in pharmacy ◽

10.24926/iip.v10i4.2303 ◽

2019 ◽

Vol 10 (4) ◽

pp. 18

Author(s):

Heather Randles ◽

Nina Abraham ◽

Michael J. Schuh

Keyword(s):

Breast Cancer ◽

Endocrine Therapy ◽

Male Breast Cancer ◽

White Male ◽

Recurrent Breast Cancer ◽

Adjuvant Endocrine Therapy ◽

Male Breast ◽

Breast Cancer Patients ◽

Potential Benefits ◽

Recurrent Breast

The objective is to report a case of recurrent breast cancer in a poor CYP2D6 metabolizer male patient on tamoxifen, and how pharmacogenomic (PGx) testing can play an important role in selecting appropriate adjuvant endocrine therapy. The case examined here is a 60-year-old white male diagnosed with recurrence of breast cancer. The patient was prescribed tamoxifen four years prior as adjuvant endocrine therapy after initial treatment with surgery. PGx testing ordered at the time of recurrence revealed patient is a poor metabolizer of CYP2D6, which may decrease the efficacy of tamoxifen. The results prompted a change in therapy to an aromatase inhibitor (AI). This case illustrates the potential benefits of preemptive PGx testing in a male breast cancer patient to assist in selecting appropriate adjuvant therapy based on how the patient metabolizes medications. In addition, PGx testing encourages patient involvement by emphasizing the association of genetics in determining treatment. The ultimate goal in performing these tests is to individualize treatment to improve safety and efficacy while minimizing adverse drug reactions. Article Type: Case Study

Download Full-text